Category : Healthcare and Pharmaceuticals | Published at : May-2019 | Delivery Format : PDF | Status: Published | Pages : 190
Introduction
According to Acumen Research and Consulting, the global Epigenetics Diagnostic Market is expected to grow at noteworthy CAGR around 7 % throughout the forecast period and reach around US$ 18 billion by 2026.
The report provides analysis of global Epigenetics Diagnostic market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.
Increasing cancer and other chronic diseases and increasing geriatric populations are key market drivers. It is expected to fuel market growth with the presence of organisations, including the International Human Epigenome Consortium, the National Cancer Institute (NCI) and the National Health Institute (NIH). They support R&D and product development practices in the epigenetic field. These organizations encourage funding and support The NIH funds epigenetic research through the epigenomics common funding programme, which supports new epigenetic research around the world.
Market Dynamics
These organizations are expected to be motivated to finance research and development programs with the need to understand epigenetic changes at the molecular level and development of therapeutic solutions. Moreover, research initiatives through novel epigenetic research serve as a driving force on the market as efforts such as the Epidemiology and Genomics Research Program (EGRP) in the NCI Cancer Division are supported. The number of cancer mortality estimates for every 100,000 men and women a year in the U.S. are 171,2 according to the NIH. The main factors for its high prevalence are incidence rates, mortality and survival statistics, cancer symptoms information, risk factors, early detection and initial treatments. The ICGC's focus is on genomic description, epigenomic changes, as well as transcriptomic changes in various types of tumors. The DNA Elements Encyclopedia (ENCODE) was launched in the United States. National Institute for Human Genome Research to identify all functional elements of the human genome sequence. In developing epigenomic data generation and analytics, the International Human Epigenome Consortium (IHEC), built by the NIH, can be used by epigenomic researchers. In particular, epigenetics research concentrates on the identification of treatment options for different tumor types.
The product segment of the kits will probably emerge over the forecast period as the fastest growing segment. The ready-to-use kits are produced for the detection of epigenetic modifications by many biotechnology companies. The packages are available in a range of markets, ranging from kits to chromatin immunocompression kits for nuclear acid purification, DNA methylation analysis and detection of histone changes by various enzymes. In the diagnosis of disorders due to epigenetic alterations in the early stages and during treatment, epigenetic diagnose kits are used to check therapeutic effectiveness. They work with the involvement of modificationspecific monoclonal anticorps on the basis of immunoprecipitation.
Product Outlook
In 2018, epigenetics diagnostics dominated the segment of reactors. The main types of reagents used for epigenetics are historone and DNA modifiers. PCR reagents, histones, primers, electrophoresis reagents, antimicrobial analysis reagents, and buffers are segmented in epigenetic agents into anticodies. PyroMark Q24 is one of the advanced pyro-sequencing chemistry reactives that can be better detected and quantified in the real time sequence than before. A number of technology platforms make gene, protein or cellular analysis easier and lead to innovations in epigenetic reagents. A platform for the genomic was set up by the polymerase chain reaction (PCR). Epigenetic factors like chromatin, DNA methylation and non-codingof RNAs affect gene regulation. The market for life sciences and analytical instruments is driven largely by the widespread use of reagents.
Techonology Outlook
The biggest segment was methylation of DNA in 2018. A methyl group's covalent addition in the cytosine ring leads to transcription inhibition. Sensitive modification of bisulphite followed by PCR is carried out called PCR Sensitive Methylation (MSP). Real time PCR, methyl lights, and quantitative analysis are variations of MSP for detection of methylated alleles. MALDI-TOF MS also works well for DNA methylation, currently using quantitative methods, such as alloyspecific bisulfite sequencing, South based method, bisulphite-PCR and bisulphite pyrosequencing. Advances in technology allow for the evaluation of DNA methylation in the localus on a genome-wide scale increasingly.
Due to its improved efficacy, which could be attributed to the introduction of new methods, histone acetylation would have experienced the fastest growth during the forecast period. Histone acetylation is the lysine residue enzyme embodiment of an acetyl group. Cellular processes such as the silencing of genes, chromatin transcription and dynamics, cell cycle progressions, differentiation, apoptosis, DNA replication, neuronal repression, nuclear imports and DNA repair include histone acetylation (histone acetylation). Histone Acetyl Transferases (HATs) are the enzyme involved in histone acetylation and histone deacetylases (HDACs) are the enzymes involved with deacetylation.
Application Stance
In 2018, Oncology dominated the total market with around 65% of total sales. A high impact rendering factor in the market is expected to be a higher global prevalence of cancer, along with increased cancer deaths. In addition, this segment is expected to receive a significant incomes share during the forecast period due to the introduction of new products and possible future marketing of currently underway products.
Epimutations are known to occur due to epigenetic changes, and hypermethylation and epigenetic silencing. Epimutations are known to participate in cancer etiology. A comprehensive research and development is undertaken to detect epimutations related specifically to tumor suppressor muzzling and oncogen activation. Contrary to regular mutations, epimutations are in nature reversible.
Non-oncology is thought to be the fastest growing segment, as a result of strict research & departmental and bio-pharmaceuticals initiatives undertaken by private institutions and biopharmaceutical enterprises in identification of markers of epigenetics in relation to these disorder. Extensive research for the detection of biomarkers for drug development is undertaken by private institutions and biopharmaceutical companies.
Regional Stance
The dominant regional market was North America in 2018. Market drivers include state-of - the-art technology facilities, successful initiatives, an increasing geriatric population, improved care facilities, government funding for continuous epigenetics research activities, diligent research and precise diagnostic procedures.
Moreover, the program supported by the Common Fund in the United States should boost epigenetic research covering a diverse range of conditions such as cardiovascular, metabolic and inflammatory diseases, including oncology and non-oncology.
The Asia Pacific region is expected to experience the fastest growth over the forecast period, due to increased disposable income, unresolved clinical needs of patients, increased knowledge about early diagnosis, and the availability of effective treatment in emerging countries, such as India and China.
Cases of oncology and chronic diseases are expected to increase further due to growing Geriatric population. In this region there is an increase in R&D initiatives related to epigenetic base analysis in various diseases. Consortium of EpiGen Research based in the U.K. expanded its Singapore research facility for chronic disease research, such as diabetes and obesity.
Market Segmentation
Global Epigenetics Diagnostic Market, By Product
- Reagents
- Kits
- ChIP Sequencing Kit
- Whole Genomic Amplification Kit
- Bisulfite Conversion Kit
- RNA Sequencing Kit
- Others
- Instruments
- Enzymes
- Services
Global Epigenetics Diagnostic Market, By Technology
- DNA Methylation
- Reagents
- Kits
- Instruments
- Enzymes
- Services
- Large non-coding RNA
- Reagents
- Kits
- Instruments
- Enzymes
- Services
- Histone Methylation
- Reagents
- Kits
- Instruments
- Enzymes
- Services
- Histone Acetylation
- Reagents
- Kits
- Instruments
- Enzymes
- Services
- Chromatin structures
- Reagents
- Kits
- Instruments
- Enzymes
- Services
- MicroRNA Modification
- Reagents
- Kits
- Instruments
- Enzymes
- Services
Global Epigenetics Diagnostic Market, By Application
- Oncology
- Solid Tumors
- Liquid Tumors
- Non-oncology
- Inflammatory Diseases
- Metabolic Diseases
- Infectious Diseases
- Cardiovascular Diseases
- Others
Global Epigenetics Diagnostic Market, By Geography
- North America.
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa (MEA)
The market research study on “Epigenetics Diagnostic Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global Epigenetics Diagnostic market segments with market dynamics and their impact. The report also covers basic technology development policies.
The report provides an analysis of the latest industry trends from 2015 to 2026 in all sub-segment segments and forecasts revenue and volume growth on the global, the regional and country levels. ARC has divided the global market report of medical oxygen concentrations on product, application, technology and region for this study.
Key Players & Strategies
Roche Diagnostics; Thermo Fisher Scientific, Inc.; Eisai Co. Ltd., and Novartis AG are the main players in this industry. Major players focus on expanding their enterprises to increase their market share in developing regions. In addition, strategies like mergers, purchases and new product development are adopted. In March 2015, for example, Illumina Inc. worked on a universal, next-sequence oncology diagnosis with Merck Serono.
